

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

VOLUNTARY ANNOUNCEMENT

EXCLUSIVE LICENSE AGREEMENT FOR CM326

A. INTRODUCTION

Keymed Biosciences Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that on November 20, 2021, Keymed Bioscience (Chengdu) Co., Ltd. (康諾亞生物醫藥科技(成都)有限公司, “**Chengdu Keymed**”), a wholly-owned subsidiary of the Company, has entered into an agreement (the “**Agreement**”) with Shanghai JMT-BIO Technology Co., Ltd (上海津曼特生物科技有限公司, “**JMT-BIO**”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Limited (“**CSPC**”), in relation to the exclusive licensing and commercialization of the product CM326 (an anti-TSLP recombinant humanized monoclonal antibody, the “**Product**”) in the treatment of moderate to severe asthma, chronic obstructive pulmonary disease (COPD) and other respiratory system diseases (the “**Field**”).

Pursuant to the Agreement, Chengdu Keymed will grant the exclusive rights to the Product to JMT-BIO for the development and commercialization of the Product in the Field in the People’s Republic of China (excluding the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan) (the “**Territory**”), and for becoming the marketing authorization holder.

In consideration for the exclusive rights, JMT-BIO agreed to pay an upfront payment of RMB100,000,000 and development milestone payments of up to RMB100,000,000 subject to the development progress of the Product in the Territory to Chengdu Keymed. JMT-BIO also agreed to pay potential sales milestone payments and royalties to Chengdu Keymed based on the net sales of the Product achieved in the Territory.

B. ABOUT CM326

CM326 is a Class 1 innovative drug researched and developed by Chengdu Keymed with the new mechanism of action and global independent intellectual property rights targeting thymic stromal lymphopoietin (TSLP), and is the first drug developed for this target that is under clinical study in China. TSLP is one of the initiators of inflammatory cascade response. The inhibition of TSLP can interfere with the inflammation in the early stage, preventing immune cells from releasing proinflammatory cytokines. TSLP is closely related to the occurrence of allergic diseases such as atopic dermatitis, asthma and chronic rhinosinusitis, and it has been proved to be an effective target for Th2 low asthma (covering about 40% of the population). Pre-clinical studies have shown that CM326 has a good safety profile and excellent efficacy, and various in vitro pharmacodynamics studies have proved that the biological activities of this product are significantly superior to those of overseas drugs developed for their targets. Based on the positive results obtained by CM326 in the Phase I clinical study in healthy volunteers, Chengdu Keymed will rapidly advance the clinical trials for various indications of CM326. CM326 has currently obtained the permission for clinical trials focusing on asthma and moderate to severe atopic dermatitis indications in China, and the Product will commence Phase II clinical trial soon.

C. ABOUT JMT-BIO TECHNOLOGY CO., LTD.

JMT-BIO Technology Co., Ltd. is a wholly owned subsidiary of CSPC, a company listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code 1093. CSPC is a leading pharmaceutical group in China with strong innovation, R&D and marketing capability. Its strong product portfolio includes products in the therapeutic areas of nervous system diseases, oncology, anti-infectives and cardiovascular diseases.

D. OTHERS

The Company is also currently engaged in other collaboration arrangements with CSPC as set forth in the Company's prospectus dated June 25, 2021 and the announcement dated September 23, 2021. The Company believes that the strategic alliance will further strengthen the collaboration between the Company and CSPC, where the two parties will further utilize their respective advantages, and coordinate their resources to jointly promote the development of drugs in the Field.

This announcement is made by the Company on a voluntary basis to provide information to shareholders and potential investors of the Company. There is no assurance that the Product will ultimately be successfully developed, marketed and/or commercialized by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of Directors
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, November 22, 2021

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Dong LYU, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive Directors; Prof. Xiao-Fan WANG, Prof. Yang KE, Mr. Cheuk Kin Stephen LAW and Prof. Linqing LIU as independent non-executive Directors.